• Cancer

    Brain Cancer Survival Improved Following FDA Approval of Bevacizumab

A new population-based study has found that patients with glioblastoma who died in 2010, after the U.S. Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.  

Click here for news release

Journalists: B-roll and sound bites with lead author Derek Johnson, M.D., are available in the downloads